Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study

Autor: Johnson, Melissa L, Zvirbule, Zanete, Laktionov, Konstantin, Helland, Aslaug, Cho, Byoung Chul, Gutierrez, Vanesa, Colinet, Benoît, Lena, Herve, Wolf, Martin, Gottfried, Maya, Okamoto, Isamu, van der Leest, Cor, Rich, Patricia, Hung, Jen-Yu, Appenzeller, Christina, Sun, Zhaowen, Maag, David, Luo, Yan, Nickner, Caroline, Vajikova, Alena, Komarnitsky, Philip, Bar, Jair

Publikováno v: Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2021, 16 (9), pp.1570-1581. ⟨10.1016/j.jtho.2021.03.012⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2021, 16 (9), pp.1570-1581. ⟨10.1016/j.jtho.2021.03.012⟩

International audience; Introduction - Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::fe21e82d78530eb4170cc8a17d37dabe
https://hal.science/hal-03194617